Loading…
Allogene Therapeutics, Inc. is projected to rise to $2.60 by 2027, a +30% move from its current price of $2.00. ALLO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $1.94 | $2.00 | $2.06 | +0.04% |
| Jul 13 | $1.92 | $2.00 | $2.09 | +0.09% |
| Jul 14 | $1.91 | $2.00 | $2.11 | +0.13% |
| Jul 15 | $1.89 | $2.00 | $2.12 | +0.18% |
| Jul 16 | $1.88 | $2.00 | $2.14 | +0.22% |
| Jul 17 | $1.87 | $2.01 | $2.15 | +0.26% |
| Jul 18 | $1.86 | $2.01 | $2.17 | +0.31% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.86 | $2.01 | $2.17 | +0.31% |
| Week 2 | $1.81 | $2.01 | $2.24 | +0.62% |
| Week 3 | $1.77 | $2.02 | $2.30 | +0.93% |
| Week 4 | $1.74 | $2.02 | $2.36 | +1.24% |
| Week 5 | $1.71 | $2.03 | $2.41 | +1.56% |
| Week 6 | $1.69 | $2.04 | $2.46 | +1.87% |
| Week 7 | $1.67 | $2.04 | $2.50 | +2.18% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company that develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies.
The company is developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Allogene Therapeutics, Inc. (ALLO) is a healthcare stock with a current price of $2.00 and a market cap of $690.31M, ranking 2796 in market size.
The stock sits in the healthcare sector as a clinical stage company focused on allogeneic CAR T cell therapies. The 2026 forecast shows an average price of $2.00 with a range from $1.35 to $2.86, and a neutral sentiment for that year.
Looking further out, the forecast projects rising averages through 2030 and beyond, with an average of $2.92 in 2030 and bullish sentiment continuing through 2050. The 2050 forecast shows an average of $11.39 with a max of $21.50 and a strong ROI of 469.6%, reflecting substantial long-term upside potential alongside notable uncertainty.
A major floor 23.0% below — a decisive break under it would weaken the trend.
The nearest floor, 11.0% below — buyers have tended to step in here.
The nearest ceiling, 12.5% above — a clean break opens room to run.
A major ceiling 53.0% above — clearing it would confirm fresh momentum.
Key ALLO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ALLO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.09 | Sell | $2.07 | Sell |
| MA 10 | $2.11 | Sell | $2.08 | Sell |
| MA 20 | $2.05 | Sell | $2.07 | Sell |
| MA 50 | $2.07 | Sell | $2.09 | Sell |
| MA 100 | $2.24 | Sell | $2.06 | Sell |
| MA 200 | $1.82 | Buy | $1.94 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.28 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -41.83 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -3.38 | Sell |
| Bollinger %B (20,2) | 0.37 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.05 | Buy |
| Awesome (5,34) | 0.05 | Buy |
| Ultimate (7,14,28) | 41.03 | Neutral |
| Momentum (10) | -0.06 | Sell |
| Aroon Osc (25) | 48.00 | Buy |
| Hull MA (9) | 2.08 | Sell |
| ADX (14) | 9.64 | Neutral |
| ATR (14) | 0.06 | Info |
The 30-day technical picture is bullish overall.
RSI(14) is 50, and the stock trades with a near-term tilt toward the upside as it sits near the moving averages. The SMA50 is $2.07 and the SMA200 is $1.82, placing the price of $2.00 in between near-term support and resistance dynamics.
The price faces resistance at $2.25 and has support at $1.78. The 30-day price range spans from $1.65 to $2.42, indicating a relatively tight range with some upside room. Annualized volatility stands at 60, adding to the short-term positioning considerations.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.35 | $2.00 | $2.86 | 0% | Neutral | |
| $2.06 | $2.60 | $3.47 | +30% | Bullish | |
| $2.17 | $2.82 | $3.93 | +41% | Bullish | |
| $2.10 | $2.79 | $4.01 | +40% | Bullish | |
| $2.14 | $2.92 | $4.29 | +46% | Bullish | |
| $2.26 | $3.15 | $4.73 | +57% | Bullish | |
| $2.48 | $3.51 | $5.39 | +76% | Bullish | |
| $2.90 | $4.18 | $6.53 | +109% | Bullish | |
| $3.07 | $4.49 | $7.14 | +125% | Bullish | |
| $3.25 | $4.83 | $7.79 | +141% | Bullish | |
| $4.27 | $6.82 | $11.73 | +241% | Bullish | |
| $6.29 | $11.39 | $21.50 | +470% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.35 | $2.00 | $2.41 | +0.00% |
| August 2026 | $1.76 | $2.08 | $2.53 | +4.19% |
| September 2026 | $1.75 | $2.08 | $2.56 | -0.08% |
| October 2026 | $1.72 | $2.06 | $2.56 | -0.96% |
| November 2026 | $1.79 | $2.16 | $2.70 | +4.52% |
| December 2026 | $1.87 | $2.27 | $2.86 | +5.36% |
Click any year to see its month-by-month ALLO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect ALLO to range from $1.35 to $2.86 through 2026. The $2.00 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The ALLO price prediction for 2027 points to an average of $2.60 (low $2.06, high $3.47) — a potential gain of +30% on today's $2.00. Momentum favours further upside here.
In 2028, ALLO is projected to trade between $2.17 and $3.93, averaging $2.82 — a potential gain of +41% from today's $2.00. That is up +9% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Allogene Therapeutics, Inc.'s 2029 outlook centres on $2.79, within a $2.10 to $4.01 range. That is -1% versus the projected 2028 average. That marks a +40% change versus current levels. Momentum favours further upside here.
By 2030, ALLO could reach as high as $4.29, with a base case around $2.92 and support toward $2.14 — roughly +46% from $2.00. Buyers look set to stay in control over this stretch.
Expect ALLO to range from $2.26 to $4.73 through 2031. The $3.15 average target implies a +57% move from current prices. That is up +8% on the projected 2030 average. Momentum favours further upside here.
The ALLO price prediction for 2032 points to an average of $3.51 (low $2.48, high $5.39) — a potential gain of +76% on today's $2.00. Buyers look set to stay in control over this stretch.
In 2033, ALLO is projected to trade between $2.90 and $6.53, averaging $4.18 — a potential gain of +109% from today's $2.00. That is up +19% on the projected 2032 average. Momentum favours further upside here.
Allogene Therapeutics, Inc.'s 2034 outlook centres on $4.49, within a $3.07 to $7.14 range. That is up +8% on the projected 2033 average. That marks a +125% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, ALLO could reach as high as $7.79, with a base case around $4.83 and support toward $3.25 — roughly +141% from $2.00. Momentum favours further upside here.
Expect ALLO to range from $4.27 to $11.73 through 2040. The $6.82 average target implies a +241% move from current prices. That is up +41% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The ALLO price prediction for 2050 points to an average of $11.39 (low $6.29, high $21.50) — a potential gain of +470% on today's $2.00. Momentum favours further upside here.
Investing $1,000 in ALLO today (≈ 500 ALLO) could be worth
$5,695.56
+$4,695.56 (+470%) by 2050 · US Dollar
Based on the average projected ALLO price of $11.39 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ALLOwould be worth at today's price.
$1,000 invested in ALLO on Jul 10, 2025 (≈ 793.6508 ALLO) would be worth
$1,587.3
+$587.3 (+58.7%) today · 1.59× · US Dollar
Based on a ALLO entry price of $1.26 vs. today's $2.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.08 | $961.54 | -3.8% |
| 1 month ago | $1.78 | $1,123.6 | +12.4% |
| 3 months ago | $2.72 | $735.29 | -26.5% |
| 6 months ago | $1.67 | $1,197.6 | +19.8% |
| 1 year ago | $1.26 | $1,587.3 | +58.7% |
| All time (5.0y) ago | $23.67 | $84.5 | -91.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ALLO forecast.
Our base-case forecast reaches $4.00 around 2033.
Implied market cap at $4.00: $1.38B
In the multi-year view, the forecast shows a bullish trajectory with rising average prices and meaningful upside potential. The 2027 average is $2.60, followed by $2.82 in 2028 and $2.79 in 2029, with 2030 at $2.92 and 2031 at $3.15, 2032 at $3.51, 2033 at $4.18, 2034 at $4.49, and 2035 at $4.83.
The long-range outlook strengthens further, with the 2040 average at $6.82 and the 2050 average at $11.39. The corresponding maximums rise to $11.73 in 2040 and $21.50 in 2050. Across these years, the forecast shows bullish sentiment and escalating ROI figures up to 469.6% by 2050.
These are estimates of future prices and are not guarantees. They reflect what could occur under the modeled scenarios, and actual results will depend on a range of factors that can influence biotechnology equities, including clinical results, regulatory developments, and market conditions.
Tap a question to reveal the answer.
2030: min $2.14, avg $2.92, max $4.29 with an ROI of 45.9% and bullish sentiment.
The forecast shows a bullish sentiment from 2027 onward with rising averages and positive ROI in 2027 (29.8%), 2028 (41.2%), 2029 (39.7%), 2030 (45.9%), and beyond, though these are estimates and not guarantees.
Yes. The 2050 forecast lists an avg of $11.39, a max of $21.50, a min of $6.29, and an ROI of 469.6%, with bullish sentiment.
Current price is $2.00 and market cap is $690.31M.
Bullish sentiment with RSI(14) at 50. SMA50 is $2.07, SMA200 is $1.82. Support is $1.78 and resistance is $2.25. The 30-day range is $1.65 to $2.42, and annualized volatility is 60.
Allogene Therapeutics, Inc. Community Discussion
0Share your Allogene Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.